Vivera Pharmaceuticals, Inc. and diagnostic test distributor Areum Bio LLC today announced the establishment of a channel partnership to expand Access Bio, Inc.’s CareStart™ COVID-19 rapid antigen test and the FDA emergency use authorization (EUA) product line Distribution). Areum Bio is already the main distributor of CareStart™ COVID-19 rapid antigen test from New Jersey manufacturer Access Bio, and will seek to strengthen its supply chain work through Vivera’s extensive network of healthcare providers and organizations.
As universities, businesses, airlines, and public places use routine testing as part of their back-to-school, work, travel, and party agreements, the availability of reliable COVID-19 testing remains a key necessity. The efficiency of the EUA-authorized Point-of-Care (POC) CareStart™ rapid antigen test, coupled with Vivera’s extensive distribution capabilities, will ensure easier access to rapid diagnostic test solutions.
The United States has achieved major milestones in overcoming the peak of the pandemic, but because vaccination rates are below ideal levels and the threat of new variants continues to emerge worldwide, it is still vital that the country continues to follow COVID-19 testing protocols to reduce the spread . The distribution partnership between Vivera, Areum Bio and Access Bio will facilitate rapid testing as quickly as possible. As an authorized distributor of CareStart™ rapid antigen testing, Vivera intends to expand its coverage to ensure that healthcare providers and patients have access to rapid testing to help ensure the safety of our community.
“This co-branding collaboration marks a new strategic alliance for Vivera,” said Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals. “The company is honored to work with Areum Bio and Access Bio to provide fast and reliable EUA-authorized COVID-19 testing for our healthcare organizations and patients nationwide. By expanding the scope of testing, Vivera will ensure that our partners and patients, Especially the disadvantaged communities that depend most on us can achieve measurable results.”
“This is an excellent opportunity for Areum Bio to collaborate with the reputable pharmaceutical company Vivera to distribute CareStart™ COVID-19 rapid antigen test nationwide,” said Dr. Jong Kim, Areum Bio’s president. “Through this partnership, using our common passion and expertise, we will be able to provide fast and reliable testing kits to communities across the country in a more timely and effective manner. We believe that even the most innovative medical equipment, They are also worthless unless distributed to patients who need them. At Areum Bio, we firmly believe that we will succeed only when our innovative devices reach patients and providers and meet their goals. Therefore, we always work hard. , To deliver our products to customers in a fast and effective manner.”
Through their strategic distribution partnerships, Vivera, Areum Bio, and Access Bio hope to support the country’s safe and seamless return to normal by increasing the availability of high-quality rapid testing nationwide.
CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic test used to qualitatively detect the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or nasal swab specimens collected directly from suspects Individuals with COVID-19 are suspected of COVID-19 when their health care provider takes two tests within the first five days of the onset of symptoms, or from individuals with no symptoms or other epidemiological reasons, at least 24 hours between tests And no more than 48 hours.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendment (CLIA) of 1988, 42 USC §263a, and these laboratories meet the requirements for performing medium, high, or exempt complexity tests. The test is authorized to be used in point-of-care (POC), that is, in-patient care environments operated under CLIA exemption certificates, compliance certificates, or certification certificates.
For more information, please visit you or contact us on LinkedIn, Facebook, Twitter or Instagram.
Areum Bio, LLC is a reliable medical device distributor and has established a trustworthy partnership with Access Bio, Inc. Areum Bio is a subsidiary of Ivy Pharma Inc. headquartered in New Jersey. The company cooperates with many business partners and has established distribution channels worldwide. In addition to its 15-year distribution history in the United States, it has To help, Areum Bio also stepped up to help quickly distribute reliable coronavirus test kits through its extensive network. The company is committed to continuously promoting public health and human well-being by providing accurate and reliable diagnostic test kits in a timely manner.
Access Bio, Inc. is a reputable diagnostic manufacturer located in New Jersey, still focusing on the research, development and production of infectious disease diagnostics. Access Bio is committed to the prevention and early diagnosis of infectious diseases through the research, development and manufacture of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Based on the greatest needs and the potential to do good, the company cooperates with partners around the world, including the Bill and Melinda Gates Foundation, the World Health Organization, and the United Nations Children’s Fund.
Post time: Jul-01-2021